Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association

被引:2263
|
作者
Heidenreich, Paul A.
Trogdon, Justin G.
Khavjou, Olga A.
Butler, Javed
Dracup, Kathleen
Ezekowitz, Michael D.
Finkelstein, Eric Andrew
Hong, Yuling
Johnston, S. Claiborne
Khera, Amit
Lloyd-Jones, Donald M.
Nelson, Sue A.
Nichol, Graham
Orenstein, Diane
Wilson, Peter W. F.
Woo, Y. Joseph
机构
关键词
AHA Scientific Statements; cardiovascular diseases; forecasting; US costs; cost analysis; COLLEGE-OF-CARDIOLOGY; ACUTE MYOCARDIAL-INFARCTION; RISK-FACTOR PROFILE; PRIMARY PREVENTION; ADOLESCENT OVERWEIGHT; PERFORMANCE-MEASURES; ECONOMIC BURDEN; BLOOD-PRESSURE; TASK-FORCE; ADULT;
D O I
10.1161/CIR.0b013e31820a55f5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results-To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. Conclusions-These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD. (Circulation. 2011;123:933-944.)
引用
收藏
页码:933 / 944
页数:12
相关论文
共 50 条
  • [32] Electronic Cigarettes A Policy Statement From the American Heart Association
    Bhatnagar, Aruni
    Whitsel, Laurie P.
    Ribisl, Kurt M.
    Bullen, Chris
    Chaloupka, Frank
    Piano, Mariann R.
    Robertson, Rose Marie
    McAuley, Timothy
    Goff, David
    Benowitz, Neal
    [J]. CIRCULATION, 2014, 130 (16) : 1418 - 1436
  • [33] Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association
    de Ferranti, Sarah D.
    de Boer, Ian H.
    Fonseca, Vivian
    Fox, Caroline S.
    Golden, Sherita Hill
    Lavie, Carl J.
    Magge, Sheela N.
    Marx, Nikolaus
    McGuire, Darren K.
    Orchard, Trevor J.
    Zinman, Bernard
    Eckel, Robert H.
    [J]. DIABETES CARE, 2014, 37 (10) : 2843 - 2863
  • [34] Type 1 Diabetes Mellitus and Cardiovascular Disease A Scientific Statement From the American Heart Association and American Diabetes Association
    de Ferranti, Sarah D.
    de Boer, Ian H.
    Fonseca, Vivian
    Fox, Caroline S.
    Golden, Sherita Hill
    Lavie, Carl J.
    Magge, Sheela N.
    Marx, Nikolaus
    McGuire, Darren K.
    Orchard, Trevor J.
    Zinman, Bernard
    Eckel, Robert H.
    [J]. CIRCULATION, 2014, 130 (13) : 1110 - U156
  • [35] The American Heart Association's Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association
    Beaton, Andrea
    Kamalembo, Flavia B.
    Dale, James
    Kado, Joseph H.
    Karthikeyan, Ganesan
    Kazi, Dhruv S.
    Longenecker, Chris T.
    Mwangi, Jeremiah
    Okello, Emmy
    Ribeiro, Antonio Luiz P.
    Tauber, Kathryn A.
    Watkins, David A.
    Wyber, Rosemary
    Zimmerman, Meghan
    Carapetis, Jonathan
    [J]. CIRCULATION, 2020, 142 (20) : E358 - E368
  • [36] Status of Cardiovascular Disease and Stroke in Hispanics/Latinos in the United States A Science Advisory From the American Heart Association
    Rodriguez, Carlos J.
    Allison, Matthew
    Daviglus, Martha L.
    Isasi, Carmen R.
    Keller, Colleen
    Leira, Enrique C.
    Palaniappan, Latha
    Pina, Ileana L.
    Ramirez, Sarah M.
    Rodriguez, Beatriz
    Sims, Mario
    [J]. CIRCULATION, 2014, 130 (07) : 593 - 625
  • [37] Guidance to Reduce the Cardiovascular Burden of Ambient Air Pollutants: A Policy Statement From the American Heart Association
    Kaufman, Joel D.
    Elkind, Mitchell S. V.
    Bhatnagar, Aruni
    Koehler, Kirsten
    Balmes, John R.
    Sidney, Stephen
    Burroughs Pena, Melissa S.
    Dockery, Douglas W.
    Hou, Lifang
    Brook, Robert D.
    Laden, Francine
    Rajagopalan, Sanjay
    Bishop Kendrick, Katherine
    Turner, Jay R.
    [J]. CIRCULATION, 2020, 142 (23) : E432 - E447
  • [38] Hormone replacement therapy and cardiovascular disease - A statement for healthcare professionals from the American Heart Association
    Mosca, L
    Collins, P
    Herrington, DM
    Mendelsohn, ME
    Pasternak, RC
    Robertson, RM
    Schenck-Gustafsson, K
    Smith, SC
    Taubert, KA
    Wenger, NK
    [J]. CIRCULATION, 2001, 104 (04) : 499 - 503
  • [39] Aspirin as a therapeutic agent in cardiovascular disease - A statement for healthcare professionals from the American Heart Association
    Hennekens, CH
    Dyken, ML
    Fuster, V
    [J]. CIRCULATION, 1997, 96 (08) : 2751 - 2753
  • [40] Cigarette smoking, cardiovascular disease, and stroke - A statement for healthcare professionals from the American Heart Association
    Ockene, IS
    Miller, NH
    [J]. CIRCULATION, 1997, 96 (09) : 3243 - 3247